Explore 3 Stock Ideas & Industry Insights Download Free Report

800-234-336
Shopping Cart 0
countryflagNZ
Login

EKF Diagnostics Holdings Plc

Healthcare GB EKF

26.4GBX
-0.1(0.38%)

Last update at 2026-06-03T15:35:00Z

Day Range

26.4027.40
LowHigh

52 Week Range

19.0032.00
LowHigh

Fundamentals

  • Previous Close 26.50
  • Market Cap104.15M
  • Volume187690
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA10.16M
  • Revenue TTM51.56M
  • Revenue Per Share TTM0.12
  • Gross Profit TTM 26.48M
  • Diluted EPS TTM-

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax 7.09M 6.26M 2.13M -8.94200M 21.43M
Minority interest - -0.33500M -0.37900M -0.52500M -0.30700M
Net income 2.12M 6.24M 2.35M -9.57600M 15.85M
Selling general administrative - 18.08M 19.68M 23.18M 17.71M
Selling and marketing expenses - - 1.80M - -
Gross profit 26.48M 21.48M 23.86M 24.04M 39.37M
Reconciled depreciation - 4.72M 5.47M 6.66M 5.88M
Ebit - 6.43M 2.21M 1.91M 21.75M
Ebitda 6.75M 11.16M 7.68M 8.57M 27.68M
Depreciation and amortization - 4.72M 5.47M 6.66M 5.93M
Non operating income net other - - - - -
Operating income 6.75M 6.46M 2.08M 1.91M 21.75M
Other operating expenses 44.82M 43.93M 50.53M 64.86M 60.09M
Interest expense 0.15M 0.17M 0.07M 0.10M 0.36M
Tax provision - -0.31400M -0.60000M 0.63M 5.28M
Interest income - 0.17M 0.12M 0.13M 0.04M
Net interest income - 0.00300M 0.05M 0.03M -0.31200M
Extraordinary items - - - - -
Non recurring - - - - -
Other items - - - - -
Income tax expense 4.55M -0.31400M -0.60000M 0.63M 5.28M
Total revenue 51.56M 50.19M 52.61M 66.64M 81.84M
Total operating expenses 19.73M 15.02M 21.78M 22.26M 17.62M
Cost of revenue 25.08M 28.71M 28.75M 42.60M 42.47M
Total other income expense net 0.34M -0.19600M 0.05M -10.85300M -0.31200M
Discontinued operations - - - - -
Net income from continuing ops - 6.58M 2.73M -9.57600M 16.16M
Net income applicable to common shares - - - -10.10100M 15.85M
Preferred stock and other adjustments - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 81.14M 81.75M 80.85M 89.29M 115.12M
Intangible assets 3.75M 5.05M 5.80M 8.65M 14.51M
Earning assets - - - - -
Other current assets - 1.87M 4.54M -0.01000M 13.98M
Total liab 10.86M 8.53M 12.63M 14.77M 20.38M
Total stockholder equity 69.05M 72.33M 67.12M 73.35M 94.12M
Deferred long term liab - - - 3.96M 3.44M
Other current liab 1.69M 4.70M 4.53M 2.44M 0.47M
Common stock 4.34M 4.54M 4.54M 4.55M 4.64M
Capital stock - 4.54M 4.54M 4.55M 4.64M
Retained earnings 52.14M 55.00M 48.76M 52.46M 74.26M
Other liab - - - 2.49M 5.20M
Good will 24.14M 23.88M 24.43M 25.12M 27.38M
Other assets - - - 4.88M 0.01M
Cash 15.83M 14.30M 6.02M 11.58M 20.34M
Cash and equivalents - - - - -
Total current liabilities 7.42M 6.44M 9.50M 11.74M 13.65M
Current deferred revenue - - - - 3.00M
Net debt -14.44900M -12.98300M -1.92100M -10.03100M -17.71200M
Short term debt 0.40M 0.84M 3.48M 1.01M 1.10M
Short long term debt - 0.00000M 2.99M 0.14M 0.27M
Short long term debt total 1.39M 1.32M 4.10M 1.55M 2.63M
Other stockholder equity 7.44M 7.39M 7.39M 16.34M 15.22M
Property plant equipment - - - 21.71M 17.87M
Total current assets 30.88M 28.55M 25.56M 31.76M 47.55M
Long term investments - - - - -
Net tangible assets - - - 43.53M 52.23M
Short term investments - -1.28900M - - -
Net receivables 6.74M 6.28M 6.23M 10.76M 13.98M
Long term debt - 0.00000M 0.00000M 0.00000M 0.43M
Inventory 8.30M 7.39M 8.77M 9.43M 13.24M
Accounts payable 5.33M 0.90M 0.98M 8.29M 9.08M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 5.12M 5.40M 6.44M - -
Additional paid in capital - - - - -
Common stock total equity - - - - -
Preferred stock total equity - - - - -
Retained earnings total equity - - - - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other - 0.23M 0.28M 1.12M 7.79M
Deferred long term asset charges - - - - -
Non current assets total 50.26M 53.19M 55.29M 57.53M 67.56M
Capital lease obligations - 1.32M 1.11M 1.41M 1.93M
Long term debt total - - - - -
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments - -2.66200M -5.64200M -8.93200M -5.47700M
Change to liabilities - - - -2.17700M 1.22M
Total cashflows from investing activities -2.33800M -2.66200M -5.64200M -8.93200M -5.47700M
Net borrowings - -3.00000M 2.86M -1.68400M -0.82100M
Total cash from financing activities -5.86300M -4.07700M -3.64600M -11.03900M -6.15500M
Change to operating activities - - - - -
Net income 2.12M 6.24M 2.13M -8.94200M 21.43M
Change in cash 1.53M 6.58M -3.85200M -8.76300M -1.57200M
Begin period cash flow 14.30M 7.73M 11.58M 20.34M 21.91M
End period cash flow 15.83M 14.30M 7.73M 11.58M 20.34M
Total cash from operating activities 9.71M 13.66M 6.31M 9.69M 10.24M
Issuance of capital stock - - - - 0.00000M
Depreciation - 4.72M 5.47M 6.66M 5.88M
Other cashflows from investing activities - -0.41600M -0.37700M - 0.04M
Dividends paid - - 5.45M 5.46M 5.10M
Change to inventory - 0.77M -0.74500M -0.81500M -4.60100M
Change to account receivables - -0.12200M 2.50M 1.28M -3.27400M
Sale purchase of stock - - 0.00000M -3.89600M -
Other cashflows from financing activities -0.87200M -1.07700M -1.06400M -1.07100M -0.87400M
Change to netincome - - - 14.85M -4.84000M
Capital expenditures 1.53M 2.25M 6.97M 5.83M 5.65M
Change receivables - - - - -
Cash flows other operating - - - - -
Exchange rate changes - - - - -
Cash and cash equivalents changes - - - - -
Change in working capital -0.51300M 0.67M -1.04900M -1.71600M -6.65800M
Stock based compensation - 0.00000M -0.00200M -0.30800M -6.58600M
Other non cash items 8.10M 2.02M -0.24100M 14.00M 0.03M
Free cash flow 8.18M 11.41M -0.66400M 3.86M 4.59M

Peer Comparison

Sector: Healthcare Industry: Medical Devices

Company Change (GBX) Price (GBX) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
EKF
EKF Diagnostics Holdings Plc		 -0.1 0.38% 26.40 - 34.97 2.02 1.46 1.72 7.01
SN
Smith & Nephew PLC		 17.00 1.56% 1108.50 23.24 12.47 1.70 2.59 2.67 10.76
NIOX
NIOX Group PLC		 2.00 3.39% 61.00 28.20 18.73 4.84 3.41 4.35 13.85
CREO
Creo Medical Group PLC		 -0.375 2.65% 13.75 - - 199.36 0.74 6.21 8.16
AOTI
AOTI Inc		 - -% 59.00 18.25 8.10 0.64 2.76 0.94 8.31

Reports Covered

Stock Research & News

View All

Profile

EKF Diagnostics Holdings plc engages in the design, development, manufacture, and sale of diagnostic instruments, reagents, and other ancillary products in the Americas, Europe, the Middle East, Asia, Africa, and internationally. The company offers DiaSpect Tm hand-held hemoglobin analyzer; Hemo Control, a hemoglobin and hematocrit analyzer; and HemataStat II, a microhematocrit centrifuge that provides a quantitative hematocrit reading for six blood samples. It also provides glucose and lactate analyzers, such as Biosen C-Line GP+ and C-Line Clinic; Quo-Lab HbA1c, a desktop point-of-care analyzer for measuring glycated hemoglobin; Quo-Test HbA1c, fully automated hemoglobin A1c analyzer for the monitoring and management of diabetes; and STAT-Site W Beta-Hydroxybutyrate analyzer. In addition, the company offers Creamatocrit Plus, a breast milk analyzer; QuPID and True20 pregnancy tests; Lactate Scout Vet, a handheld lactate analyzer for veterinary care; Hemo Vet, a point-of-care hemoglobin and hematocrit analyzer; Lactate Scout Sport, a lactate analyzer for sports performance; Biosen series for sports; and EKF Link, a data management solution that integrates point-of-care analyzers. Further, it offers Beta-Hydroxybutyrate LiquiColor for monitoring ketosis; RaPET, a range of immunoassay kits; QuStick Strep A for Strep A infection treatment; Hema-Screen Lab Pack for detection of colorectal cancer; PrimeStore MTM, a molecular transport medium that preserves and stabilizes DNA and RNA; Uri-Trak 120M urine analyzer; and clinical chemistry reagents, controls, and standards. Additionally, the company provides precision fermentation, custom bioprocessing, and contract manufacturing solutions; and diagnostic enzymes that include arylacylamidase, beta-hydroxybutyrate dehydrogenase, and salicylate hydroxylase. The company was founded in 1990 and is headquartered in Cardiff, the United Kingdom.

EKF Diagnostics Holdings Plc

Avon House, Cardiff, United Kingdom, CF64 2EZ

Key Executives

Name Title Year Born
Mr. David Michael Salter CEO & Exec. Director 1961
Mr. Marc Peter Davies CFO & Director 1980
Mr. Andrew Webb Chief Exec. Officer of Ekf Molecular NA
Mr. Salim Hamir F.C.A. Company Sec. NA
Mr. Julian Huw Baines M.B.E. Executive Chairman 1964
Mr. Stephen Young A.C.M.A. CFO & Executive Director 1963
Mr. Gavin Joseph Jones CEO & Director 1980

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.